| Empire Eye Physicians | |
|
16010 E Indiana Ave, Spokane Valley, WA 99216 | |
| (509) 928-8040 | |
| (509) 928-0784 |
| Full Name | Empire Eye Physicians |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 16010 E Indiana Ave, Spokane Valley, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205939709 | NPI | - | NPPES |
| 7081029 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Provider Name | Mark A Kontos |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1114938990 PECOS PAC ID: 5799784369 Enrollment ID: I20101111000090 |
News Archive
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
Firefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world's most dangerous bacteria.
› Verified 9 days ago
| Provider Name | Christopher W Sturbaum |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1457361560 PECOS PAC ID: 4880693456 Enrollment ID: I20110112000576 |
News Archive
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
Firefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world's most dangerous bacteria.
› Verified 9 days ago
| Provider Name | Casey D Claypool |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1447480579 PECOS PAC ID: 6305009036 Enrollment ID: I20120516000622 |
News Archive
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
Firefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world's most dangerous bacteria.
› Verified 9 days ago
| Provider Name | Jason Albert Croskrey |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1609118439 PECOS PAC ID: 8729496245 Enrollment ID: I20210422002043 |
News Archive
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
Firefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world's most dangerous bacteria.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Empire Eye Physicians 16010 E Indiana Ave, Spokane Valley, WA 99216 Ph: (509) 928-8040 | Empire Eye Physicians 16010 E Indiana Ave, Spokane Valley, WA 99216 Ph: (509) 928-8040 |
News Archive
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
Firefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world's most dangerous bacteria.
› Verified 9 days ago